Decoding the Covid-19 connection with diabetes
A growing base of evidence suggests people are significantly more likely to develop diabetes in the months following a Covid-19 infection, and health systems need to…
By
Abi Millar
Latest articles
All Articles
Five pharma cybersecurity breaches to know and learn from
The transition to digital, expedited by the Covid-19 pandemic, has opened up new cybersecurity concerns.
By
Ferring draws closer to a microbiome breakthrough
Ferring and subsidiary Rebiotix are developing a microbiota-based live biotherapeutic, RBX2660, against recurrent C. diff.
By
Fighting India’s ‘black fungus’ epidemic
What exactly is black fungus, and what can be done to combat the rise of this condition alongside Covid-19?…
By
Blood plasma production: OK for the UK?
With the UK’s blood plasma donated ban lifted, Abi Millar looks into the risk-benefit analysis of producing plasma domestically.
By
Are competition authorities tightening the rules on pharma M&A?
The US Federal Trade Commission has initiated a multilateral working group to ensure that mergers and acquisitions in the…
By
Rewriting the pharma supply chain for a post-pandemic world
The pandemic has demonstrated the critical need for resilience and agility in pharma supply chains.
By
Academic-industry collaboration: how can licensing and partnerships be made smoother?
Abi Millar digs into academic-industry collaboration, and how this source of innovation could be better leveraged in the future.
By
Regenerative medicine: ready for the big leagues?
What is at the cutting-edge of regenerative medicine in 2021, and are these complex products ready to break into…
By